Table 1.
Dosages and duration of therapy at 7 years and survival outcomes at 5 years based on CML-AP diagnosis
| Hematologic status | Clonal evolution | Prior AP diagnosis | All patients diagnosed with CML-AP | |||||
|---|---|---|---|---|---|---|---|---|
| QD (n = 67) | BID (n = 64) | QD (n = 55) | BID (n = 61) | QD (n = 34) | BID (n = 31) | QD (n =1 57) | BID (n = 160) | |
| Average daily dose, mg (range) | 119 (26–216) | 108 (13–178) | 94 (20–162) | 97 (22–171) | 106 (34–174) | 87 (21–206) | NR | NR |
| Median duration of therapy, months (range) | 8.3 (0.0–90.1) | 9.2 (0.5–86.1) | 21.9 (0.5–92.9) | 20.7 (0.4–84.6) | 16.9 (0.12–93.2) | 20.3 (1.6–83.8) | 15.4a (0.00–67.0) | 12.5a (0.4–66.3) |
| Median duration of therapy excluding interruption, months (range) | 7.4 (<0.1–89.1) | 8.3 (0.5–85.4) | 20.9 (0.5–92.9) | 16.7 (0.3–83.7) | 15.4 (0.2–91.4) | 17.3 (1.6–81.7) | NR | NR |
| PFS, % (95% CI) | 20.7 (11.5–31.9) | 21.3 (10.2–35.2) | 42.1 (27.4–56.1) | 41.5 (25.0–57.2) | 31.1 (15.8–47.8) | 24.0 (7.1–46.1) | 30.5 (22.6–38.5) | 30.3 (20.9–39.6) |
| OS, % (95% CI) | 32.8 (21.1–44.9) | 45.6 (32.3–58.0) | 52.6 (37.9–65.3) | 67.9 (53.5–78.7) | 54.3 (35.9–69.4) | 60.2 (40.4–75.2) | 45.0 (36.8–53.2) | 57.6 (49.5–65.7) |
AP accelerated phase, BID twice a day, CI confidence interval, CML chronic myeloid leukemia, NR not reported, OS overall survival, PFS progression-free survival, QD once a day
aDuration of therapy for entire CML-AP population calculated at 5 years